Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PL9654 and PL9655 are proprietary small molecule melanocortin receptor (MCR) agonists being developed by Palatin Technologies in collaboration with Boehringer Ingelheim. These compounds are designed to treat retinal diseases, specifically diabetic retinopathy and diabetic macular edema, by targeting the melanocortin receptor system. Their mechanism of action involves activating natural resolution pathways to reduce inflammation, stabilize the blood-retinal barrier, decrease vascular endothelial growth factor (VEGF) signaling, and provide neuroprotection to retinal ganglion cells. The program is currently in the preclinical stage of development following a strategic partnership announced in August 2025.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PL9654 (Palatin Technologies, Inc.).